- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 39-53 of
153 results
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 5
Document
IPR2022-00215, No. 1013-60 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 5 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1011 Exhibit: Ex 1011 Vital and Health Statistics, Serum Lipids of Adults 20 74 Yea...
Document
IPR2022-00215, No. 1011-13 Exhibit - Ex 1011 Vital and Health Statistics, Serum Lipids of Adults 20 74 Years United States, 1976 80, 11242, Natl Health Survey, US Dept Health Human Servs M...
|
|
Cite Document
1023 Exhibit: Ex 1023 Exhibit U to Plaintiffs First Amended Complaint,Ballantyne et...
Document
IPR2022-00215, No. 1023-28 Exhibit - Ex 1023 Exhibit U to Plaintiffs First Amended Complaint,Ballantyne et al, Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester AMR101 Therapy in Sta...
|
|
Cite Document
1044 Exhibit: Ex 1044 US Patent Application Publication No 20070021504 A1 to Yo...
Document
IPR2022-00215, No. 1044-49 Exhibit - Ex 1044 US Patent Application Publication No 20070021504 A1 to Yokoyama et al (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1037 Exhibit: Ex 1037 Hikmas Motion to Dismiss from Amarin Pharma, Inc et al vs H...
Document
IPR2022-00215, No. 1037-42 Exhibit - Ex 1037 Hikmas Motion to Dismiss from Amarin Pharma, Inc et al vs Hikma Pharms USA Inc et al, CA No 20 1630 D Del (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1036 Exhibit: Ex 1036 Scheduling Order from Amarin Pharma, Inc et al vs Hikma Ph...
Document
IPR2022-00215, No. 1036-41 Exhibit - Ex 1036 Scheduling Order from Amarin Pharma, Inc et al vs Hikma Pharms USA Inc et al, CA No 20 1630 D Del (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 8
Document
IPR2022-00215, No. 1013-63 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 8 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1006 Exhibit: Ex 1006 Satoh et al, Purified Eicosapentaenoic Acid Reduces Small D...
Document
IPR2022-00215, No. 1006-5 Exhibit - Ex 1006 Satoh et al, Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C Reactive Protein in Metabolic Syndr...
|
|
Cite Document
1029 Exhibit: Ex 1029 FDA Briefing Document, Endocrinologic and Metabolic Drugs...
Document
IPR2022-00215, No. 1029-34 Exhibit - Ex 1029 FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting regarding ANCHOR trial Oct 16, 2013 (P.T.A.B. Nov. ...
|
|
Cite Document
1028 Exhibit: Ex 1028 Notice of Allowability from US Patent Office re US Patent App...
Document
IPR2022-00215, No. 1028-33 Exhibit - Ex 1028 Notice of Allowability from US Patent Office re US Patent Application No 13768,906 Sept 30, 2013 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1005 Exhibit: Ex 1005 Yokoyama et al, Effects of Eicosapentaenoic Acid on Major C...
Document
IPR2022-00215, No. 1005-4 Exhibit - Ex 1005 Yokoyama et al, Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients JELIS a Randomized Open Label...
|
|
Cite Document
1048 Exhibit: Ex 1048 Lipitor atorvastatin calcium Label 092007
Document
IPR2022-00215, No. 1048-53 Exhibit - Ex 1048 Lipitor atorvastatin calcium Label 092007 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1010 Exhibit: Ex 1010 Day 2 Jan 14, 2020 Trial Transcript from Amarin Pharma, Inc...
Document
IPR2022-00215, No. 1010-11 Exhibit - Ex 1010 Day 2 Jan 14, 2020 Trial Transcript from Amarin Pharma, Inc v Hikma Pharms USA Inc, No 16 2525 D Nev Testimony of Dr Budoff (P.T.A.B. Nov. 3...
|
|
Cite Document
1019 Exhibit: Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hik...
Document
IPR2022-00215, No. 1019-25 Exhibit - Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hikma Pharms USA Inc, No 16 2525 D Nev Part 4 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1020 Exhibit: Ex 1020 Plaintiffs Infringement Contentions from Amarin Pharma, Inc...
Document
IPR2022-00215, No. 1020-21 Exhibit - Ex 1020 Plaintiffs Infringement Contentions from Amarin Pharma, Inc et al vs Hikma Pharms USA Inc et al, CA No 20 1630 D Del (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
